Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an agile team with a championship mindset.

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

<p>Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate risk, and comply with emerging AI regulations.</p> ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

<p>Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.</p> ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year.

Creating and bringing new medicines to patients is a uniquely complicated process. It requires robust scientific research, business acumen, tremendous financial investment, and patience — even when ...

The treatment landscape for autoimmune and inflammatory diseases has evolved through three distinct phases. The first era, dating back as far as the 1960s, relied on broad immunosuppressants such as ...